drugset / Trial / NCT00121719

An Open Label Dose Escalation Study Of E7080

NCT00121719

Phase 1 Completed 82 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.

Timeline

Start
2005-07-01
Primary completion
2009-06-19
Completion
2019-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule Oral

Indications